The role of adiponectin in inflammatory gastrointestinal diseases

Gut

Volumn 58, Issue 3, 2009, Pages 317-322

  Schäffler, Andreas ^a,b   Schölmerich, Jürgen ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLITAZONE DERIVATIVE; INTERLEUKIN 6; LEPTIN; PLACEBO; REACTIVE OXYGEN METABOLITE; RESISTIN; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR;

ACUTE PANCREATITIS; ASCITES; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CROHN DISEASE; DISEASE COURSE; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIVER CIRRHOSIS; LIVER FIBROSIS; MESENTERY PANNICULITIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANNICULITIS; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ULCERATIVE COLITIS;

ACUTE DISEASE; ADIPONECTIN; ANIMALS; FEMALE; GASTROENTERITIS; HEPATITIS; HUMANS; MALE; MICE; PANCREATITIS;

EID: 61649124115     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.159210     Document Type: Review

References (68)

1. Scherer PE, Williams S, Fogliano, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
2. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003;278:40352-63.
3. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006;110:267-78.
4. Schäffler A, Schölmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol 2007;28:393-9.
5. Schäffler A, Müller-Ladner U, Schölmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006;27:449-67.
6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
7. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008;121:326-30.
8. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
9. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
10. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med 2004;10:126-7.
11. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
12. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
13. Schäffler A, Schölmerich J, Büchler C. Mechanism of disease: Adipocytokines and visceral adipose tissue: Emerging role in non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:273-80.
14. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005;33:138-44.
15. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
16. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004;40:177-84.
17. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-807.
18. Kamada Y, Matsumoto H, Tamura S, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007;47:556-64.
19. Matsumoto H, Tamura S, Kamada Y, et al. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 2006;12:3352-8.
20. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006;8:264-80.
21. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116:1776-83.
22. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
23. Mendez-Sanchez N, Chavez-Tapia NC, Zamora-Valdes D, et al. Adiponectin, structure, function and pathophysiological implications in non-alcoholic fatty liver disease. Mini Rev Med Chem 2006;6:651-6.
24. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006;6:606-14.
25. Martinez J, Johnson CD, Sanchez-Paya J, et al. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006;6:206-9.
26. Lankisch PG, Schirren CA. Increased body weight as a prognostic parameter for complications in the course of acute pancreatitis. Pancreas 1990;5:626-9.
27. Porter KA, Banks PA. Obesity as a predictor of severity in acute pancreatitis. Int J Pancreatol 1991;10:247-52.
28. Johnson CD, Toh SK, Campbell MJ. Combination of APACHE-II score and an obesity score (APACHE-O) for the prediction of severe acute pancreatitis. Pancreatology 2004;4:1-6.
29. Sultan S, Baillie J. What are the predictors of post-ERCP pancreatitis, and how useful are they? J Pancreas 2002;3:188-94.
30. Schäffler A, Landfried K, Völk M, et al. Potential of adipocytokines in predicting peripancreatic necrosis and severity in acute pancreatitis: pilot study. J Gastroenterol Hepatol 2007;22:326-34.
31. Schäffler A, Paul G, Fürst A, et al. Serum resistin and leptin levels predict severity of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:418-9.
32. Tukiainen E, Kylanpaa ML, Ebeling P, et al. Leptin and adiponectin levels in acute pancreatitis. Pancreas 2006;32:211-4.
33. Araki H, Nishihara T, Matsuda M, et al. Adiponectin plays a protective role in caerulein-induced acute pancreatitis in high-fat diet-fed mice. Gut 2008;57:1431-40.
34. Zyromski NJ, Mathur A, Pitt HA, et al. A murine model of obesity implicates the adipokine milieu in the pathogenesis of severe acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008;295:G552-8.
35. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
36. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79:955-8.
37. Colombel JF. The adipose tissue as a source of proinflammatory signals in Crohn's disease? In: Herfarth H, ed. Targets of treatment in chronic inflammatory bowel disease: proceedings of the Falk Symposium. Dordrecht, Boston: Kluwer Academic Publishers, 2002: 99-104.
38. Fazio VW. Regional enteritis (Crohn's disease): indications for surgery and operative strategy. Surg Clin North Am 1983;63:27-48.
39. Smedh K, Olaison G, Nystrom PO, et al. Intraoperative enteroscopy in Crohn's disease. Br J Surg 1993;80:897-900.
40. Knutson H, Lunderquist A. Vascular changes in Crohn's disease. Am J Roentgenol Radium Ther Nucl Med 1968;103:380-5.
41. Schäffler A, Herfarth, H. Creeping fat in Crohn's disease: travelling in a creeper lane of research? Gut 2005;54:742-4.
42. Schäffler A, Schölmerich J, Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue - emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:103-11.
43. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007;56:577-83.
44. Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000;190:196-202.
45. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
46. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:847-55.
47. Yamamoto K, Kiyohara, T, Murayama, Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005;54:789-96.
48. Levine JA, Jensen MD, Eberhardt NL, et al. Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. J Clin Invest 1998;101:1557-64.
49. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007;19:1070-4.
50. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27:987-91.
51. Paul G, Schäffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 2006;12:471-7.
52. Schäffler A, Fürst A, Büchler C, et al. Secretion of RANTES (CCL5) and IL-10 from mesenteric adipose tissue and from creeping fat in Crohn's disease: regulation by steroid treatment. J Gastroenterol Hepatol 2006;21:1412-8.
53. Schäffler A, Fürst A, Büchler C, et al. VEGF secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease. J Gastroenterol Hepatol 2006;21:1419-23.
54. Nishihara T, Matsuda M, Araki H, et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 2006;131:853-61.
55. Fayad R, Pini M, Sennello JA, et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007;132:601-14.
56. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006;134:105-13.
57. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-61.
58. Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002;360:1410-8.
59. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-38.
60. Nakajima A, Katayama K, Mayumi T. [PPARgamma-gene therapy using an adenovirus vector for inflammatory bowel disease]. Nippon Yakurigaku Zasshi 2003;122:309-16.
61. Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003;124:1315-24.
62. Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-9.
63. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688-95.
64. Parra-Davila E, McKenney MG, Sleeman D, et al. Mesenteric panniculitis: case report and literature review. Am Surg 1998;64:768-71.
65. Nicholson AC. Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med 2004;14:8-12.
66. Andus T, Gross V, Holstege A, et al. High interleukin-6 concentrations in hepatic ascites. Dig Dis Sci 1994;39:219-20.
67. Andus T, Gross V, Holstege A, et al. Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity of patients with ascites. J Hepatol 1992;15:378-81.
68. Wiest R, Leidl F, Kopp A, et al. Peritoneal fluid adipokines: ready for prime time? Eur J Clin Invest (in press)